Stereotaxis - Q2 2023

Transcript

Operator (participant)

Good morning. Thank you for joining us for Stereotaxis' second quarter 2023 earnings conference call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations, and as such, constitute forward-looking statements within the meanings of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company in the future to be materially, materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update these statements. At this time, all participants have been placed on a listen-only mode.

The floor will be opened for questions and comments following the presentation. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis.

David Fischel (Chairman and CEO)

Thank you, operator, and good morning, everyone. We are pleased to return to robust double-digit growth in the second quarter with a 28% year-over-year increase in revenue. System revenue for the quarter reflects partial revenue recognition on two Genesis systems, both of which are being installed this summer at hospitals in the US and Europe. During the second quarter, we received orders for two Genesis systems, one from a new greenfield hospital in Europe and the 2nd as an upgrade of an Niobe system to Genesis in the US. The net effect of the orders we received and the revenue recognized led to a slight increase in system backlog, which as of quarter end, stands at $60 million. We expect similar or increased levels of system revenue in the upcoming quarters as our backlog is converted into revenue.

We also continue to see a healthy pipeline of replacement cycle and greenfield hospitals interested in our robotic technology, which is expected to continue to contribute to backlog and provide confidence in sustained year-over-year revenue growth. Genesis system sales remain the primary driver of our growth as we work towards advancing a robust innovation strategy towards commercialization. Our recurring revenue in the quarter was impacted by the loss of royalty payments that we no longer receive from Johnson & Johnson, as well as J&J catheter production shortages, which pressured procedure volumes. Each individually presented a high single-digit headwind to recurring revenue. The J&J catheter production shortages, which pressured procedure volumes throughout the first half of this year, seem to have been resolved in July, and we expect procedures to rebound to more normal levels in the third quarter.

On our last call, we hinted at a special announcement we had planned for the Heart Rhythm Society conference. A highlight of the last quarter was the announcement at that conference of a global strategic collaboration with Abbott to integrate Abbott's latest EnSite X mapping system with Stereotaxis' robots. The integration of our technologies makes the use of Abbott's leading mapping system an attractive option for the community of robotic electrophysiologists who have long desired increased choice in mapping. It enhances the overall physician experience, streamlines procedural workflow, and supports the improved treatment of patients who have complex arrhythmias. From a strategic perspective, this was a major leap forward in our effort to build an open ecosystem where the benefits of robotics can be paired with a broad range of diagnostic and therapeutic technologies.

It will also significantly support the launch and more rapid adoption of our proprietary next generation of ablation catheter, MAGiC. There was significant excitement at HRS around our integration announcement. We had an opportunity to educate the broader Abbott commercial leadership team on our technology, and Abbott dedicated a space in their booth to showcase our collaboration. Abbott's software is currently released in Europe, and last month we celebrated the first integrated EnSite robotic procedures at Erasmus Medical Center in the Netherlands and Marienhaus St. Elisabeth Hospital in Germany. These sites continue to do integrated procedures, and other sites are moving through the adoption process. We expect integration to be available in the U.S. late this year as Abbott's software and connectivity cable are approved in the U.S.

The main drive for significant joint adoption of our technologies will take place concurrent with the MAGiC launch, so we anticipate a continued shift and diversification towards Abbott's EnSite system until then. We had expected to receive CE mark and launch the MAGiC catheter in Europe this summer. While our regulatory submission was in line with multiple historical precedents and direct verbal feedback we had received from the European notified body, the notified body's interpretation of the new MDR regulations led them to request first in-human data prior to approval. We were surprised by the decision, but have responded rapidly in designing a clinical protocol and putting together all the clinical trial documentation needed for submission to hospital ethics committees and relevant national authorities. Acute data on two dozen patients from one single center should be sufficient....

To reduce dependency or risk of delays at any individual site, we have engaged and begun submitting documentation to multiple sites, several of which have first-in-human trial experience. We expect to start patient enrollment in the trial in the fourth quarter and complete the acute data collection on the couple dozen patients rapidly, allowing a restart of the MAGiC CE Mark review early next year. The availability of this clinical data will ultimately support a more robust launch for MAGiC in Europe, as we plan to use the trial to gain experience, data, and materials to support the launch. In the US, we are progressing with the submission of our IDE application. In parallel, we are exploring with the FDA the possibility of an alternative regulatory route, which would accelerate our path to bring MAGiC to US physicians and patients.

Beyond MAGIC, we continue to meaningfully advance our multi-pronged, robust innovation strategy. These innovation efforts include a smaller, self-shielding robot that frees us from the extensive planning and construction currently necessary to adopt robotics, a family of interventional guide wires and guide catheters that expand the benefits of our robots into new endovascular indications, a digital surgery, hardware, and software offering, enabling broad operating room connectivity, and a full electrophysiology product ecosystem being built in collaboration with MicroPort for the Chinese market. Development and refinement of the smaller self-shielding robot has gone well and is near completion. Commercial launch of the robot is predicated, however, on either the MAGIC catheter or our magnetic guide wire achieving regulatory clearance.

We therefore want to balance pursuing regulatory approval for the robot early enough such that we de-risk regulatory approval and ensure it is available when those interventional devices come to market, but not too early, such that we lose the ability to create an exciting launch for the robot. We plan to now submit the robot for 510(k) clearance and CE mark at year-end, at a similar time to when we expect to submit for the robotic magnetic guidewires. That should allow for approval and launch of our new robot with a guidewire for vascular indications in 2024. Availability of the new robot paired with MAGiC will occur as soon as MAGiC gains its first regulatory approval, which we believe should be possible in mid-2024.

In China, MicroPort is making significant progress in bringing together our joint product ecosystem and preparing for a commercial launch. MicroPort continues to expect Genesis NMPA approval in early 2024. Mapping integration with their Columbus mapping system is complete and waiting for availability of a magnetic ablation catheter, which will be submitted for regulatory approval before year-end. MicroPort expects availability of this comprehensive product ecosystem in mid-2024 and is starting to build awareness and excitement for what we will be launching together. The Asia Pacific Heart Rhythm Society Conference is taking place this year in early September in Hong Kong. Stereotaxis technology will be prominently showcased at the conference.

The Society for Cardiac Robotic Navigation received an extensive session at the conference, during which our robotic technology will be showcased in three live-streamed cases, including long-distance telerobotic procedures performed from the podium to hospitals hundreds and thousands of miles away. During the conference, MicroPort will also showcase for the first time, its new magnetic ablation catheter being navigated by Genesis, integrated with its mapping system. This activity and the growing excitement we see in the market bodes well for a strong launch next year. I recognize our path hasn't been easy and that progress on our strategic innovation efforts has been slower than originally anticipated. There have been various external factors serving as headwinds, including changing regulatory goalposts, supply chain difficulties, and personnel challenges across the industry that impact contract manufacturing partners.

Internally, we have also been doing things that are new to us as an organization, such as focusing on disposable interventional devices. We are advancing multiple, very significant and innovative projects with lean teams. I take responsibility for providing optimistic expectations. That said, my excitement for what we are building has not waned. I see ourselves as being on the cusp of a strategic transformation as we advance a new foundational product ecosystem that makes robotics broadly accessible and impactful across endovascular surgery. We have clear line of sight to a near-term future with strategic independence, an attractive revenue model, broad robot accessibility, and multi-indication opportunity. Kim will now provide commentary on our financial results, and then I'll make a few financial comments as well before opening the call to Q&A. Kim?

Kimberly Peery (CFO)

Thank you, David, and good morning, everyone. Revenue for the second quarter of 2023 totaled $7.9 million, growth of 28% from $6.2 million in the prior year's second quarter. This growth was primarily due to higher revenue recognition on Genesis robotic system sales, partially offset by discontinued royalties from Johnson & Johnson. System revenue of $3.3 million reflects revenue recognition on the delivery of two Genesis systems. Recurring revenue for the quarter of $4.6 million was predominantly impacted by both the absence of a J&J royalty and J&J catheter production shortages, which pressured procedure volume. The J&J catheter shortage has been largely resolved, and we expect procedures to rebound to normal levels in the third quarter.

Gross margin for the second quarter of 2023 was 53% of revenue, with recurring revenue gross margin of 79% and system gross margin of 18%. Recurring revenue gross margin remains consistent with recent quarters, and system gross margin continues to reflect significant allocation of overhead expenses over low manufacturing volume. Operating expenses in the quarter of $9.5 million include $2.6 million in non-cash stock compensation expense. Excluding non-cash stock compensation expense, adjusted operating expenses were $6.9 million, compared to the prior year's adjusted operating expenses of $7.2 million. We continue to spend significant amounts on our research and development efforts and are working in a focused fashion to reduce operating expenses where doing so won't impede our progress.

Operating loss and net loss in the second quarter were $5.3 million and $5 million, compared to approximately $5.2 million for both in the previous year. Adjusted operating loss and net loss for the second quarter, excluding non-cash stock compensation expense, were $2.7 million and $2.4 million. Negative free cash flow for the second quarter was $2.9 million. At the end of the second quarter, we had cash and cash equivalents of $23.9 million and no debt. We expect a significant reduction in cash use in the second half of this year, particularly as we slow investment in inventory. We expect to end the year with between $22 million and $24 million in cash with no debt. I will now hand the call back to David.

David Fischel (Chairman and CEO)

Thank you, Kim. We are aware of the importance of maintaining financial strength and ensuring our existing balance sheet is capable of advancing our innovations to market and funding their commercialization. We've invested significantly over the last several quarters in our new headquarters and on inventory for both Genesis and the next generation robot. Those investments are largely behind us. We're balancing an overall posture of financial discipline with continued investment in the key drivers of technological progress and revenue growth. Our backlog and continued capital sales activity give us confidence in sustained momentum and in ending the year with double-digit annual revenue growth and a strong cash position. As our innovation pipeline comes to market, we expect that growth to accelerate from those launches. We look forward to now taking your questions. Operator, can you please open the line to Q&A?

Operator (participant)

Thank you. If you would like to ask a question, please press star followed by one on your telephone keypad. In the interest of time, we ask that you please limit yourself to one question and one follow-up. Thank you. Our first question comes from Frank Takkinen from Lake Street Capital Markets. Please go ahead. Your line is open.

Frank Takkinen (Analyst)

Great, thanks for taking the questions. Wanted to start with one on second half placement expectations. I think, David, you mentioned you expect a similar level of system revenues for Q2 and Q3 going forward. I was hoping you could speak a little bit more around that. What kind of visibility do you have into that? Is planned, is there any construction that could hold it up? Just trying to understand where we should be setting the models for system revenues in the second half.

David Fischel (Chairman and CEO)

Hey, Frank. Good morning, sir. So we've kind of got into a pace where I think we feel very comfortable with two systems being recorded as revenue as a type of lower bound of what we would expect in any given quarter. It is very hard still to estimate in any quarter exactly how many will go through. It's a, it's there is a lot outside of our control on that. And obviously, the volatility between two or three or four makes a big difference in the numbers, even though it's kind of individual units that are that are kind of driving all of that.

We think that kind of modeling, too, as a lower bound is the safe thing, and we will have quarters where we're obviously above that, but that's kind of how we're, how we're looking at things right now.

Frank Takkinen (Analyst)

Okay, that's helpful. Then for my follow-up, I was just hoping to get a little more color on the Abbott partnership. Any immediate impact you're seeing in the field, and if there's anything you can help with quantification on, on how impactful this could be, maybe how much share Abbott has in the market, how frequently Abbott integration was brought up throughout the adoption process for new users, and any other color you could provide to, to really exemplify the Abbott partnership.

David Fischel (Chairman and CEO)

Sure. The Abbott partnership is, is... Was a highly strategic one for us, we're delighted that we were able to announce it. It has been many years in the making. Generally, if you look at the electrophysiology field, from a mapping system perspective, it is a duopoly between Johnson & Johnson and Abbott. There are other mapping systems obviously out there. We obviously have the integration collaboration with Acutus, Boston Scientific has a mapping system. Medtronic is working on a mapping system. Other companies, internationally, like MicroPort, have mapping systems. In the US and Europe, still, Johnson & Johnson and Abbott have more or less a duopoly on, on the majority of the market share.

And historically, Stereotaxis has only been integrated with Johnson & Johnson's mapping system, and the lack of integration with Abbott was viewed as, as limiting for many of the physicians who would have preferred to use Abbott's mapping system. This has, obviously, clinical implications because when you provide more choice to physicians, you allow them to use the robot with less of a, of a, of a, of a, less of a kind of a choice where they have to give up other things that they've been looking for. We're also integrated with the latest version of the Abbott software, so that allows obviously the latest versions of mapping functionality with the robotic system, which is a positive.

From a strategic perspective, this will be highly beneficial for the launch of the MAGiC catheter because it does allow the MAGiC catheter to enter the market, tied with the latest mapping innovation. That will kind of support MAGiC's adoption in a significant fashion. From a purely quantitative financial perspective right now, I'd say that there's a psychological benefit to the announcement that we had that I think supports hospitals that are thinking about adopting robotics. There are also some physicians that, as integration arc is available, will prefer to shift into that mapping environment and will start to do more procedures in that environment. I would not think that there is a dramatic shift where that changes adoption dramatically in a way that you see it in the numbers overall, in the short term.

I think that you will see most of the impact there in the adoption of the MAGiC catheter, which will be accelerated significantly by this integration.

Frank Takkinen (Analyst)

Perfect. That's good color. I'll stop there. Thanks for taking the questions.

David Fischel (Chairman and CEO)

Thanks a lot, Frank.

Operator (participant)

Our next question comes from Adam Maeder from Piper Sandler. Please go ahead. Your line is open.

Adam Maeder (Managing Director and Senior Research Analyst)

Hi, David. Hi, Kim. Good morning, and thank you for taking the questions. Wanted to start on the MAGiC catheter and just, I, I guess, try and better understand timelines in Europe. It sounds like you're going to start the enrollment in the human study in Q4. Review process from the regulatory body kind of restarts early next year. Is mid-year or Q3 2024 just reasonable, a reasonable assumption for approval and launch? That's, that's question one. Question two would be just maybe you can flesh out the alternative regulatory route that you referenced for MAGiC when we're talking about the US pathway, and then I had 1 follow-up. Thanks.

David Fischel (Chairman and CEO)

Okay. Hi, Adam. Good morning, sir. In Europe, as we described in the prepared remarks, we scrambled. There was a lot of work to be done after we learned, after we received that feedback from the notified body in Europe. There was a lot of work to be done to organize a clinical trial protocol, to make sure that clinical trial protocol was both very fitting with what the notified body would want to see in terms of data, and very reasonable in terms of what physicians could enroll and could be done kind of in a efficient fashion at a hospital setting. There were many documentations that are needed to gain ethics committee and national approvals, that you need just to support those processes.

Kind of the entire team here worked in a, in a very nice fashion to, to kind of organize ourselves and be able to submit documentation to hospitals in Europe. We started engaging. While we are confident that data from a single site would be sufficient for the notified body, we didn't want to be dependent on one site. Obviously, this is new to us to run a pre-approval trial, and so kind of we didn't want to be dependent on any individual site, and so we engaged with many of our users. We got very enthusiastic feedback from many of our users in Europe who were excited to do a trial like this, and fortunately, several of them have experience doing first-in-human studies in cardiac ablation.

We've started submitting documentation at sites in Europe. From what we've heard, and it's fairly consistent at several of these centers, a review process is oftentimes two months, three months, kind of in that type of ballpark. Enrollment in this trial should be very, very rapid. It's all comer arrhythmias, we're talking about acute data. That is something that should enroll in this time span of definitely less than one month to do full enrollment and have data. We think that kind of having that data in the fourth quarter, receiving approval from the competent authorities in individual countries in Europe, from the ethics committees of hospitals, is very reasonable in the fourth quarter.

Enrolling patients and having the acute data from them is also reasonable in that same quarter. We would obviously very quickly submit that data to the notified body so that we can restart the review of our CE mark. Given how extensive the CE mark review was with all the rounds of questions until they got to the point of telling us that they believe clinical data is necessary, I believe that that review process should be relatively shorter and streamlined. We went through rounds of questions before, obviously, that timeline of the regulatory review is outside of our control. I think that a summertime next year sounds very reasonable. It's obviously, though, outside of our control, so we, we can't say for certain.

Hopefully, we can even have earlier than that. Does that kind of answer the European path for MAGiC well?

Adam Maeder (Managing Director and Senior Research Analyst)

It, it does, David, thank you. That's, that's great color. Would love additional thoughts on the path forward for MAGiC in the US. You, I think referred to an alternative regulatory pathway. We'd love to hear a little bit more about that. I had one follow-up. Thanks.

David Fischel (Chairman and CEO)

The traditional path in the US is that filing for an IDE trial and running a pivotal US study, and obviously submission of a PMA application to FDA. We have done most of the work to be ready for that and to do that submission. We, given what we are doing in Europe, and given some of the discussions we've had, we believe there might be a reasonable likelihood that we gain an alternative path, which would be attractive. It is obviously very important for us and for the physician community that relies on robotics and for the patients they treat, that MAGiC is available for US physicians and patients as early as possible. We are cognizant of that importance.

We're grateful that we've had the opportunity to have meaningful discussions with FDA. At this point, there's not much more that I should say, but I believe that at the next quarterly earnings call, I'll, I'll definitely, or I should be able to provide much clearer guidance on our path forward in the US.

Adam Maeder (Managing Director and Senior Research Analyst)

Okay, great. Totally understand. Then for the follow-up, wanted to pivot over to the mobile robotic system. I guess the genesis of the question is just trying to, you know, better understand the strategy and timing here. I think I heard you say the plan now is to submit for 510(k) and CE mark at year-end. You know, a little bit of a push out there. I guess my question is, why not submit earlier for approval, get across the regulatory goal line, but just, you know, not launch it until you have approval for the MAGiC catheter in hand? Hopefully, that makes sense, and would love any color there. Thank you.

David Fischel (Chairman and CEO)

No, no pun intended on the genesis of the question comment there, right? We feel, we feel, we feel good with how we've been developing and the testing process for the next generation system. There is a balancing act where, as we pursue approval for a system, oftentimes even post-approval, you continue to do some improvements, some modifications in a robotic system. It's, it's, it's different than something like an interventional device, and we've continued to improve the Genesis system over time. There's a, there's a balancing act between when do you want to pull the lever on pursuing regulatory approval versus continuing to do that refinement and then pulling the regulatory lever. Our team has been laser-focused on the MAGiC regulatory process these last several weeks.

There isn't value in gaining approval for the robot prior to either MAGiC or guidewire being on the market. I think we're taking a very just a balanced approach, where we definitely want to gain, like you say, approval for the robot prior to the interventional devices being on the market in order to de-risk that dependency and to make sure it is available. On the other hand, we feel very confident with the regulatory path that exists for the robot, even given that we did Genesis very recently, and given that we've had discussions with the regulators in both their regions recently on that regulatory path again.

We feel confident in the regulatory path there, and, and we want to balance also not getting approval for a robot, six, nine months before we actually can do anything with it, and then continuing to make iterative improvements in that meantime. That's really kind of the calculus going on. I think that kind of this is a reasonable balance, and we'll, we'll be flexible if we sense that we have acceleration anywhere else in the program, then we'll, then we'll pull the trigger quicker.

Adam Maeder (Managing Director and Senior Research Analyst)

That's helpful color. Thank you.

David Fischel (Chairman and CEO)

Thank you.

Operator (participant)

Our next question comes from Alexander Nowak, from Craig-Hallum Capital. Please go ahead. Your line is open.

Alexander Nowak (Senior Research Analyst)

Hey, great. Good morning, everyone. David, I wanted to push a little bit more around the alternative paths, and I know you don't want to reveal too much until you have the game plan set, but if I'm just hearing you correctly, it sounds like you could potentially use the European data in the PMA submission and maybe could bypass some of the, some of the workflow that is needed for a PMA if you just were solely doing it in the US?

David Fischel (Chairman and CEO)

It is. Hi, Alex. It is obviously an important topic and an important question. I don't want to go into great detail of that now. I don't think it's appropriate to do so. I think that it is obviously the MAGiC catheter is highly important product in terms of ensuring that physicians that use our technology and the patients that they treat have access to robotics and the latest generation of robotics in kind of the best fashion possible. I'm grateful that the, that kind of, you know, the regulators understand that importance. We are being creative in how we're thinking about collecting data to ensure that MAGiC is a, is a, is clearly kind of an efficacious and safe device.

We're- we've been fortunate to have the opportunity to explore various ideas in a collaborative fashion. I, I, I will know more in the coming weeks, and so I believe by the next call, we'll be in a position to be able to share much more. Again, kind of our baseline path, which we are advancing and committed to, is submitting an IDE application in the near term. But there may be op- opportunities for, for an improved timeline there that would provide MAGiC to US physicians and patients in an accelerated path.

Alexander Nowak (Senior Research Analyst)

Okay, understood. Well, look forward to that update there next quarter. Sounds very interesting. Maybe on utilization, if you back out some of the one-time items here with regards to, you know, I guess maybe not one time, but, you know, the royalty, the catheter shortages. How is underlying usage and utilization with Niobe and Genesis going this quarter?

David Fischel (Chairman and CEO)

Obviously from a recurring revenue perspective, you see the hit because of the loss of the royalty. That has nothing to do with utilization. That's purely a kind of a $1 hit per procedure. On the utilization side, we were hamstrung by the shortages of J&J catheters, which did impact volumes in the second quarter. They also did impact in the first quarter before that. Overall, that a high single-digit impact to recurring revenue, the shortage of catheters and the impact on utilization. I'd say we expect, given what we've seen this high and given the commentary we've received, it seems like the shortages on catheter are largely over. We'd expect to bounce back to more normal volumes in the third quarter.

Overall, we still see utilization at Genesis accounts, being, higher than at Niobe accounts, and so we see kind of the benefit of new technology and what new technology brings to the marketplace, and so that has been kind of, good to see.

Alexander Nowak (Senior Research Analyst)

Okay, excellent. Then maybe just lastly, just how is the overall hospital environment in recent months? It might seem like based on the commentary, things are starting to break free a little bit. New placements and new orders are starting to flow in maybe a little bit easier than it has been during the pandemic.

David Fischel (Chairman and CEO)

I'd say it's a, it's mixed, where, again, I, I think I've made the comment sometimes in the past, that we are still a relatively smaller player in the field, and it's hard to take macro trends from our experience. Generally, what you described is true. We do sense multiple hospitals that are engaging with us. There are definitely hospitals that are moving forward on projects that are kind of that are able to move forward. We see kind of tenders in Europe that take place, and it kind of... That, that overall feels good. There are definitely, though, counter examples where there are hospitals that are very financially pressured and that are being very tight on any spendings or any projects.

We see, we see, we see the spectrum of experiences across our hospital customers. I think at least for us, there is a maturization of our commercial team and their ability to engage with sites. Many things snowball gradually in, in, in kind of a, in this world. I think some of the efforts that we've done over the last couple of years, to improve and to engage with sites, starts to have more of an impact, and you start to see more repeatability in the commercial teams' capabilities. It's, it's kind of, it's still not a completely open and easy environment.

I still think the macro world is a, is a world more of headwinds than tailwinds, but I think kind of we are able to overall make progress despite those headwinds.

Alexander Nowak (Senior Research Analyst)

That, that's good to hear. Well, I appreciate the update. Thank you.

David Fischel (Chairman and CEO)

Thank you very much.

Operator (participant)

Our next question comes from Joshua Jennings, from TD Cowen. Please go ahead. Your line is open.

Joshua Jennings (Managing Director and Senior Analyst)

Hi. Good morning, Dave and Kim. Thanks. Wanted to just get a refresher on the status of the US and Europe capital sales teams and any plans to build them out, and if stability is a near-term plan, what would you need to see, to change that, excuse me, strategy? Would it just be, you know, expansion of the sales funnel and just increasing levels of demand or any other triggers? I have 1 follow-up on China.

David Fischel (Chairman and CEO)

Hey, Josh, good morning. I think we've talked a little bit about the European sales team and our strategy there in the past. Overall, we view our commercial teams in the U.S., Europe, and Asia as kind of the right size. We think we have kind of a good team with smart people and capable people. We have gradually incrementally strengthened the team in Europe in anticipation of the MAGiC launch. That's been overall very gradual. I would say that we are confident that the MAGiC catheter can be launched very successfully at our existing sites in Europe with our team, and that that can be a successful launch.

We also think that we have the bandwidth, obviously, to to launch the new robot, and that to some extent just makes the work that our existing team has been doing on the capital side much easier. So I think that our technologies, as we bring them to market, can be launched very successfully with the existing teams that we have. Now, the opportunity to grow a team when you have an improved revenue model and, and, and a significantly higher disposable revenue per procedure is attractive and significant. So we do plan to channel much of that incremental gross profit that we will receive from the MAGiC catheter, from the growth in revenue from these new technologies, back into our team, back into the company.

I'd expect that as we're doing the MAGiC launch, we will move much more towards a model like other companies in the field have, where you have 1 dedicated salesperson per hospital customer. We currently have one, one person for each three or four hospitals, and that is a commercial disadvantage versus competition. When we have the MAGiC catheter available, we can very, in a very financially prudent and sustainable fashion, shift towards a kind of a more similar model to our competition. That's kind of something that we, we would be doing as we do the MAGiC launch. I think we can do that in a financially sustainable fashion, being self-funded by the launch of that new technology.

That's something we'll do gradually, kind of probably over the first year, first, 18 months or so of the launch.

Joshua Jennings (Managing Director and Senior Analyst)

Understood. I just wanted to just better understand the dynamics in China in front of MicroPort's kind of finalizing the build-out of the EP ecosystem, and incorporating, robotic magnetic navigation technology. Are there, is there a holding period here in China just for new customers? I think you've described a kind of sales funnel or pipeline of potential customers in, you know, a 12 plus range in China. Do, do we need to see Genesis approval, before those, those, that pipeline converts to, contracts? Just maybe just, to help us think through the next 12 months in front of that, that full build-out. Then just to follow up to that, is any other countries in Asia Pac, you have this, this HRS, I think Asia Pac meeting coming up in September in Hong Kong.

Any other opportunities you see, Japan or other Asia Pac countries that are intriguing for, for Stereotaxis? Thank you.

David Fischel (Chairman and CEO)

Sure. Thanks, Josh. Yeah, the, the APHRS, the Asia Pacific HRS conference, that's coming up in the beginning of September. I was very pleasantly surprised by how good of a program was arranged by the Society for Cardiac Robotic Navigation in collaboration with APHRS. They are showcasing some amazing procedures and some amazing capabilities of our technology. I think that is, that is reflective of the type of pre-commercialization work in some ways that is taking place there to build up interest and to grow kind of the, the visibility of our technology there. Overall, kind of, there is, there is some opportunity, potentially to commercialize new robots, prior to that ecosystem coming into play, next year.

I'd say that that is not, that is not the biggest focus. The real focus is how to make sure that as you have this full ecosystem available, you can have a very successful launch, and you can, together in partnership with MicroPort, take multiple percentage points of market share in a country like China, which is a significant existing market. That is really kind of the primary focus, the strategic focus and, and kind of the big win that's out there. I think kind of, as we said before, right, we expect Genesis approval in the earlier parts of next year, given the submission that had taken place already at the end of last year, and then some of the additional requests for information that took place in the first half of this year.

MicroPort will be submitting, it's kind of the next generation ablation catheter that works combined with their Columbus mapping system, and our robot, later this year. Kind of overall, we're looking at, at kind of a nice launch, probably around this time next year. Kind of I think that we do have other accounts in the Asia Pacific region outside of China, that still do procedures, that are great users of robotics. At APHRS, we will be engaging with, with, those accounts, and we'll be engaging with potential accounts, in other countries in the Asia Pacific region. I'd say that kind of from a focus perspective, we see very clear line of sight to building a substantial, business, with MicroPort in China.

So that really is kind of the biggest strategic focus, and that's where I'd expect to see the biggest change to our overall corporate trajectory from there.

Neil Chatterjee (Analyst)

Appreciate that. Thanks, Dave.

David Fischel (Chairman and CEO)

Thank you.

Operator (participant)

As a reminder, to ask a question, please press star followed by the number 1 on your telephone keypad. Our next question comes from Neil Chatterji from B. Riley. Please go ahead. Your line is open.

Neil Chatterjee (Analyst)

Good morning, and thanks for taking our questions. Yep.

David Fischel (Chairman and CEO)

Hey.

Neil Chatterjee (Analyst)

Maybe I'll just ask, I think a lot of my question's been answered, but maybe just on the... I think last call, you kinda talked about some of the preclinical studies with PFA generators. Just curious if you have any update there and, and or on any maybe development for MAGiC in PFA.

David Fischel (Chairman and CEO)

Sure. Hi, hi, Neil. I think we've also discussed this somewhat in the past, as you say, we have performed animal studies using the MAGiC catheter variant of it with PFA generators, and have got kind of nice results from that. Mechanistically, there's a lot of rationale to using the benefits of robotic magnetic navigation with pulse field energy. Pulse field energy can be very efficacious, but it does require being in contact during that short burst of therapy with the tissue, and manual catheters are less stable on the beating heart. Kind of, there's a rationale to why we provide an improved lesion when being combined with PFA. Overall, kind of we've been taking approach.

There are multiple now, many, many companies with PFA generators and PFA technology. We have been engaging and doing some technology work with various of them. I think kind of we're gonna see how, how best to create from those collaborations and some of the technology work that we've been doing, how to create an actual regulatory path. What we could do, we could shift from preclinical work to actual clinical first-in-human work, and with an actual viable regulatory path to bringing a PFA product to market. I think kind of developing of the MAGiC catheter has given us a, a foundation from which we can build on, because finally, for the first time, we own our own ablation catheter.

That kind of has been very helpful, both in, in being able to use a variant of that with PFA, and in also facilitating other companies to be able to create variants of their own catheters that can be steered in the robotic environment in collaboration with us. Again, we're kind of in the process of working with different parties on how that could kind of come to market.

Neil Chatterjee (Analyst)

Great. Thanks. Maybe just a follow-up just on OpEx. I guess, you know, with the kind of the ongoing work you have and kind of the plan work, it has me think about kind of R&D expense kind of in the back half and into 2024. Then maybe additionally, just on the pipeline, any update on your kind of work and development in the OR connectivity?

David Fischel (Chairman and CEO)

Sure. In terms of R&D expense, I'd expect that to be more or less flat. There are kind of gives and takes there, so kind of some of the projects have definitely gone through the majority of their spending, and now it's kind of more cleanup internal work with very little external spending, very little purchasing that needs to take place for them to come to completion. Others, like running clinical studies, kind of obviously ramp up the expenses. I think kind of when I look at the gives and takes of the different projects, we should expect overall spending to be more or less flat.

kind of an IDE study would be more expensive, and so, depending on how things go there, you know, next year we could see an increase in R&D expense. I'd say in the back half of this year, I'd expect it more or less equal to the first half of this year. kind of, I think generally from an OpEx perspective, we are at a relatively good level. We are making some focused reductions in expenses where that doesn't impact the progress of our technology or our commercial capability.

We also from just a OpEx and kind of GAAP earnings is not the same as cash flow, and we have still seen over the last several quarters that our cash flow has lagged behind what you would expect it to be, given the investment in inventory, both for Genesis and for the next generation robot. We have bought the vast majority of the components and supplies there for, you know, over a handful of Genesis systems and a handful of the next generation robots. A lot of that spending has been a drain on cash resources and kind of was done to reduce the risk of delays and reduce the risk of the supply chain.

kind of we will continue to spend money on, on both of those products, but I think it'll be at kind of a much lower level. Given the types of revenue and the cash inflows that we're getting from the Genesis system, they should be below that, before, below the cash inflows. I'd say that kind of obviously our, our guidance of $22 million-$24 million of cash at the end of this year, that, that is kind of representative of the fact that cash flow is going to be much better, as we don't have to continue to invest as much in that type of inventory. What was your second question? Sorry, I, I, I forgot it, Neil.

Speaker 8

Yeah, no worries. Just, just on the pipeline, just any, any update on kind of OR connectivity, you know, I guess with, like, Synchrony and Sync?

David Fischel (Chairman and CEO)

Yeah, the Sync software for connectivity, we are just at the stages where we're going to be doing an internal and limited market release as a full product in a production environment. You know, downloaded from the app stores, both iOS and Android. We'll be doing it with our internal team and then with a few of our existing customers to start making sure that it is working well, that there are no bugs, that all the features are as desired by our customers. That can serve well, both for the, you know, peer-to-peer connection between physicians and also for our team, as we do remote supportive procedures and remote, both technical and clinical support.

We're gonna be running that out, probably starting, already in 1 month from now or so. As we go through that LMR process, then we'll decide on when to do a actual kind of public formal launch. Hopefully, that kind of limited market release phase can take, will be a few months. We've already started working with hospitals. It's, there are approval process. We have a lot of experience with cybersecurity and working with hospitals, IT groups, through the due diligence required for connected technologies in the hospital environment. Probably about 80% of our hospitals have connectivity with us through VPNs currently.

that's what allows us to do remote support and allows us to gain real-time data from the robots. This solution is a much more elegant way and, and scalable way of doing connectivity with individual sites. We have a lot of experience with cybersecurity, and so we designed Synchrony in a way that, that is, I think, very good and well suited for the hospital environment. You still need to go through a new review process and, and kind of all that, that, that entails. We've actually started that process with initial hospitals, and those will probably take a few months. We're kind of it's.

I, I think kind of we've started some of that limited market release work, and, and as we go through, are able to put Sync in a few hospitals, are able to get the limited market release feedback, then we will, we will kind of plan the full launch.

Speaker 8

Great. Thanks for that, that's it for me.

David Fischel (Chairman and CEO)

Okay. Thank you, Neil.

Operator (participant)

We have no further questions in queue. I would like to turn the call back over to David Fischel for closing remarks.

David Fischel (Chairman and CEO)

Okay. Thank you very much for all your questions. We appreciate your continued support, and we look forward to working hard on your behalf in the coming months. We'll speak again next quarter. Thank you very much.

Operator (participant)

This concludes today's conference call. Thank you for your participation. You may now disconnect.